Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Yes, clinical trials can measure quality of life better than traditional health metrics alone, but only when they use the right tools and ask the right questions. While pharmaceutical trials have historically focused on whether a drug slows cognitive decline or reduces symptom severity, these numbers tell an incomplete story for people living with dementia. A person might score the same on a cognitive test whether they can still recognize their grandchildren during visits or have lost that connection entirely. Modern trial design is increasingly adding quality-of-life measures to capture what actually matters in someone’s day-to-day existence—whether they sleep better, feel less anxious, maintain independence in simple tasks, or experience fewer behavioral disturbances. This shift represents a fundamental recognition that extending survival or stabilizing test scores means little if daily life becomes unbearable.
The challenge is that measuring quality of life in dementia is complex and controversial. Unlike blood pressure or cholesterol levels, you cannot objectively quantify joy, dignity, or meaningful engagement. This has led researchers to develop structured questionnaires and assessment scales that attempt to capture what people with dementia and their caregivers actually experience. However, these tools have significant limitations, and debates continue about whether trials should rely on patient self-reporting, caregiver observations, or some combination of both. The stakes are high: pharmaceutical companies must justify expensive treatments, regulatory agencies must decide which medications to approve, and families must decide whether to enroll their loved ones in trials that may improve quality of life or simply add another line item to the side effects list.
Table of Contents
- Why Standard Clinical Measures Fall Short for Dementia Care
- The Tools and Methods Used to Measure Quality of Life in Trials
- Real-World Examples of Quality-of-Life Trials in Dementia
- How Trials Balance Cognitive Benefit Against Quality-of-Life Impact
- The Problem of Proxy Reporting and Advanced Dementia
- The Role of Family and Patient Values in Trial Design
- The Future of Trials and Quality-of-Life Measurement
- Conclusion
- Frequently Asked Questions
Why Standard Clinical Measures Fall Short for Dementia Care
Traditional clinical trials for dementia treatments typically measure cognitive function using tests like the Mini-Cog or Montreal Cognitive Assessment, which evaluate memory, attention, and reasoning through specific tasks performed during doctor visits. These tests can reliably detect whether someone is losing or maintaining certain cognitive abilities, but they reveal nothing about whether someone is happy, connected to others, or maintaining a sense of purpose. A person could maintain stable cognitive scores while spending most of their day in distress, unable to sleep, or expressing persistent anxiety. Conversely, someone might show slight cognitive decline while actually experiencing improved quality of life if their behavioral symptoms—such as aggression or wandering—have been better controlled.
The distinction becomes especially important in advanced dementia care, where slowing cognitive decline may no longer be possible, and attention shifts to comfort, dignity, and connection. In nursing home settings, for example, researchers have found that residents given certain medications experienced worse quality-of-life outcomes despite cognitive stabilization, because the side effects included sedation, reduced emotional responsiveness, or increased fall risk. This is why leading medical organizations, including the FDA, have begun requiring pharmaceutical developers to include quality-of-life assessments alongside standard cognitive measures. The addition of these measures doesn’t replace cognitive testing—it supplements it with information that better reflects whether treatment actually improves someone’s lived experience.
The Tools and Methods Used to Measure Quality of Life in Trials
Researchers use several standardized instruments to measure quality of life in dementia trials, each with different strengths and weaknesses. The Quality of Life in Alzheimer’s Disease (QoL-AD) scale asks patients about their physical health, mood, relationships, and activities, using a four-point scale; the Dementia Quality of Life Measure (DQoL) focuses on five domains including sense of self and sense of purpose; and the Bristol Activities of Daily Living Scale measures functional capacity in everyday tasks like eating, dressing, and maintaining hygiene. These tools have been validated across multiple studies, meaning researchers have confirmed they actually measure what they claim to measure and produce consistent results. However, they have a critical limitation: as dementia progresses and someone’s ability to communicate clearly diminishes, the validity of their self-reported answers becomes questionable.
This is why many trials now incorporate caregiver-reported quality-of-life assessments alongside patient reports. A family member or professional caregiver spends hours with the patient and observes subtle changes in mood, engagement, and comfort that a brief clinical encounter might miss. Yet caregiver reports introduce bias: a stressed, exhausted caregiver might rate quality of life as lower than the person with dementia would if they could clearly communicate; conversely, a caregiver motivated by guilt or hope might rate outcomes more optimistically than the actual situation warrants. Some researchers have tried to address this by using observational methods, where trained assessors spend time with patients in their home or care facility and rate quality-of-life indicators through direct observation. These methods are more time-consuming and expensive, which is why they are not used in all trials, but they can provide valuable objective data about engagement, social interaction, and behavioral responses.
Real-World Examples of Quality-of-Life Trials in Dementia
One instructive example comes from trials of lecanemab (Leqembi), a relatively new Alzheimer’s treatment that received FDA approval in 2023. The drug showed a modest slowing of cognitive decline in early-stage disease—a 27% slowing of progression over 18 months. However, the trial also measured quality-of-life outcomes, functional abilities, and caregiver burden. While lecanemab did not dramatically reverse dementia symptoms, caregivers reported somewhat improved quality-of-life scores, and patients maintained functional independence longer in certain tasks. Yet the drug comes with an important safety concern: amyloid-related imaging abnormalities (ARIA), which can cause brain microhemorrhages and microinfarcts that, in some cases, led to cognitive decline or death in trial participants. This means that for some patients and families, the quality-of-life benefit was offset or even negated by the risk, while for others, the chance to maintain independence and connection longer made the risk acceptable.
The trial data could not make that decision for individuals—it could only provide information about typical outcomes across the tested population. Another example is research into behavioral interventions and environmental modifications for dementia, such as the REACH (Resources for Enhancing Alzheimer’s Caregiver Health) trial. This study tested whether coaching and support for caregivers could improve quality of life for both the person with dementia and their family. Unlike medication trials, the interventions were not tested against a placebo but rather compared standard care to enhanced caregiver support. The results showed measurable improvements in caregiver depression and stress, and corresponding improvements in the quality of life for people with dementia—fewer behavioral disturbances, better sleep, and increased engagement in activities. This trial demonstrated that quality-of-life improvements do not always require pharmaceutical solutions and that focusing on the caregiver’s wellbeing can directly benefit the person with dementia.
How Trials Balance Cognitive Benefit Against Quality-of-Life Impact
When a drug slows cognitive decline by 25% but causes side effects that reduce quality of life—such as increased falls, reduced appetite, or emotional blunting—how should trials weigh these competing outcomes? Different stakeholders prioritize differently. A person in early dementia who highly values remaining independent might accept the side effects as a fair tradeoff. Someone in advanced dementia whose family prioritizes comfort and dignity over cognitive preservation might consider the same tradeoff unacceptable. Responsible trial reporting presents both sets of data clearly rather than emphasizing one measure at the expense of the other. However, in practice, the FDA’s regulatory approval process has traditionally weighted cognitive outcomes more heavily, which means quality-of-life improvements sometimes receive less attention in medical discussions and prescribing decisions.
This creates a practical challenge for families and healthcare providers: the published trial data may show cognitive benefit while downplaying quality-of-life concerns, or vice versa. A closer reading of the full trial results, often available in the supplementary materials or in the trial registry, usually reveals more complete information. For example, looking at dropout rates in trials can reveal how many patients discontinued treatment due to side effects, suggesting that quality of life—at least for those patients—was compromised despite any cognitive benefit. Similarly, examining secondary outcomes like changes in behavioral symptoms, sleep quality, or caregiver burden can provide a fuller picture. When considering whether a trial-tested treatment is right for an individual, it is important to ask not just whether the drug worked in the trial, but whether it worked in a way that aligns with that person’s values and priorities.
The Problem of Proxy Reporting and Advanced Dementia
One of the most significant limitations in measuring quality of life through trials is the problem of proxy reporting in advanced dementia. As someone’s cognitive abilities decline, their ability to reliably complete quality-of-life questionnaires diminishes. At some point, the person with dementia can no longer answer questions about their mood, satisfaction, or sense of purpose in a way researchers can confidently interpret. At this stage, trials must rely entirely on caregiver observations. This is not inherently wrong—caregivers often have important insight—but it creates a fundamental accountability problem: we are measuring the quality of life of a person based on observations from someone else. The observations may be accurate, but they are not the person’s direct report.
Some researchers argue that this means quality-of-life trials in advanced dementia should focus on observable outcomes like comfort, the absence of distress behaviors, engagement in preferred activities, and caregiver-assessed wellbeing, rather than assuming we can measure the subjective experience of someone who cannot communicate. Another concern is that trials are often conducted in controlled environments—hospitals, research clinics, or specialized care facilities—where quality of life may look different than in a person’s actual living situation. A treatment might appear to improve quality of life during a trial when the patient is receiving intensive monitoring and support, but the improvement may not persist at home where care is less structured or more resource-constrained. This is why some researchers advocate for pragmatic trials, which deliberately test treatments in real-world conditions with diverse patient populations and realistic care settings. However, pragmatic trials are more complex and expensive to conduct, which is why many trials continue to be conducted in more controlled settings. When reviewing trial results, it is worth considering whether the setting and level of care in the trial resembles the person’s likely real-world environment.
The Role of Family and Patient Values in Trial Design
Increasingly, trial designers are including people with dementia and their family members in decisions about which quality-of-life measures to include in studies. This participatory approach has revealed that researchers sometimes prioritize outcomes that patients and families do not actually care about most. For instance, a study might measure caregiver burden extensively but barely assess whether the person with dementia feels heard, respected, and included in family decisions. Or a trial might focus heavily on behavioral symptoms while giving little attention to whether someone still enjoys music, pets, or preferred foods.
When patients and families were invited to help design trials, the resulting studies often included novel measures, such as questions about autonomy, dignity, and engagement in meaningful activities—outcomes that standard research instruments had overlooked. This participatory approach also surfaced the issue of conflicting values: what improves a caregiver’s quality of life (such as sedating medication that reduces behavioral disturbances) might reduce a patient’s quality of life (loss of emotional responsiveness and engagement). Trials are now being designed to measure both outcomes separately rather than assuming they align. This makes trial results more complex to interpret, but it also makes them more honest and more useful for the real-world decision-making that individuals and families must do. When reading trial results, looking for separate patient and caregiver quality-of-life assessments—rather than a single combined score—provides better information for understanding what the treatment actually offered.
The Future of Trials and Quality-of-Life Measurement
As dementia research evolves, there is growing consensus that quality-of-life measurement should be central rather than secondary in trial design. The National Institute on Aging and similar research bodies have begun requiring or strongly encouraging quality-of-life endpoints in grant-funded studies. New measurement tools are being developed specifically for the realities of dementia—tools that can assess quality of life even when communication is severely limited, or that measure what researchers call the subjective wellbeing of people who may not be able to explicitly report on their own wellbeing.
Digital technologies are being tested to continuously measure certain quality-of-life indicators, such as sleep patterns, physical activity, and social engagement, rather than relying only on periodic questionnaires completed during clinic visits. Looking forward, the hope is that trials will not force a false choice between extending life, slowing disease progression, and maintaining quality of life, but will instead demonstrate which treatments can accomplish some combination of these goals for which people. This requires continued investment in research methods, more participation from people with dementia and families in trial design, and honest communication about tradeoffs. For individuals considering enrollment in a dementia trial, or deciding whether to use a treatment that was tested in a trial, the key question is not just whether the trial showed benefit, but whether the benefits measured in the trial align with what matters most to that person and their family.
Conclusion
Clinical trials can measure quality of life better than cognitive tests alone, but they do so imperfectly, with tools that work best in early dementia and become increasingly limited as the disease progresses. The addition of quality-of-life measures to dementia trials represents genuine progress in recognizing that slowing disease progression or extending life means little if daily experience becomes intolerable.
However, the way these measures are incorporated into trials, reported by researchers, and weighed in regulatory approval decisions still tends to emphasize cognitive outcomes, and quality-of-life improvements sometimes receive secondary attention in medical practice. Moving forward, the most useful trials will be those that measure quality of life in ways that align with what patients and families actually value, that report results honestly even when cognitive benefit and quality-of-life impact diverge, and that recognize that the answer to “what counts as improvement?” is not the same for everyone with dementia. For those considering dementia trials or evaluating treatments tested in trials, the takeaway is to look beyond the headline findings and examine what the trial actually measured about quality of life, who reported it, under what circumstances, and whether the measured improvements address the outcomes that matter most to the individual.
Frequently Asked Questions
If a dementia drug slows cognitive decline but causes side effects, should someone take it?
It depends on that person’s values and priorities. Looking at trial data on both cognitive and quality-of-life outcomes helps inform the decision, but the choice is personal. Some people prioritize maintaining independence as long as possible, even with side effects; others prioritize comfort and engagement. There is no universally “right” answer, which is why detailed trial data on both outcomes is essential.
How reliable are quality-of-life reports from people with advanced dementia?
As dementia advances, direct reports become less reliable, which is why trials should rely increasingly on observable measures (comfort, engagement, behavioral calm) and caregiver observations. However, caregivers have their own biases and perspectives. The most complete assessment uses multiple sources of information.
What is the difference between a patient-reported outcome and a caregiver-reported outcome in trials?
Patient-reported outcomes reflect what the person with dementia says about their own experience, while caregiver-reported outcomes reflect what family members or care staff observe. Both matter, but they can diverge. A good trial measures both separately rather than combining them into a single score.
Why don’t all dementia trials measure quality of life?
Quality-of-life measurement is time-consuming, requires specialized tools, and does not always show dramatic improvements even when cognitive benefit is present. However, regulatory and funding agencies are increasingly requiring or encouraging quality-of-life measurement, so this is gradually changing.
Where can someone find detailed quality-of-life data from dementia trials?
Published research papers, especially supplementary appendices, often contain detailed quality-of-life data. Trial registries like ClinicalTrials.gov provide summaries. Asking a healthcare provider for a detailed review of trial results, or consulting a patient advocacy organization, can also help interpret what the data means for a specific situation.
Should someone enroll in a dementia trial if quality-of-life measurement is not a primary outcome?
It depends on the trial’s purpose and other considerations. Some trials are designed to answer specific scientific questions that do not require quality-of-life measurement. However, for trials testing new treatments that might affect daily life, quality-of-life measurement should be a significant consideration. Ask the trial team what quality-of-life data will be collected and how it will be used.
You Might Also Like
- How Sensory Engagement Supports Quality of Life
- Why Families Need Studies That Reflect Daily Life
- What Dementia Care Can Learn From Procedural Memory
Related reading
- why Combined Lifestyle Changes May Matter Most
- how Exercise, Diet, Sleep, and Social Life Work Together
- can Brain Health Plans Be Personalized
- why One-Size-Fits-All Dementia Advice Falls Short
- how Doctors Prioritize Dementia Risk Factors
For more on this topic, see Alzheimer’s Association — clinical trials.
